PARP16 and lung adenocarcinoma: In summary, while PARP inhibition is a powerful radiosensitization strategy in lung adenocarcinoma, its success depends on understanding the interconnected roles of senescence, mitochondrial dysfunction, p21 signaling, and underexplored family members such as PARP16.